YUMAB GmbH

YUMAB The success of next genera- tion antibody drug development relies on comprehensive discovery technolo- gies and strategies.

YUMAB bridges the gap between re- search innovation and novel therapies. Our advanced discovery platform provi- des access to challenging targets, enables new formats, and accelerates the deve- lopment of human antibodies at a high success rate.

From target discovery to fully characte- rised lead – our experienced team leads biotech and pharma teams worldwide through the development process as your trusted, de-risking partner.

Antibody Discovery

• Advanced discovery platform for next generation biotherapeutics.
• Access to challenging targets and new formats for drug discovery at high speed and success rate.
• Fully integrated human antibody deve- lopment in one company – tailored to your needs.
• Optimized discovery solution using antigen-positive cells as a target during selection.

Antibody Libraries

• Universal human antibody libraries with more than 100 billion (1011) unique antibodies.
• Highly productive pre-selected antibo- dy sequences.
• Large epitope coverage and high hit rate.
• Flexible business conditions.

Antibody Engineering

• YUMAB® platform can be used for the engineering of externally generated already existing antibodies.
• Two in-vitro evolution technologies.